European Society for Medical Oncology
Synta Sizzles on Ganetespib Phase IIb Data in Lung Cancer
By Marie Powers
Monday, October 1, 2012
Analysts were exuberant after Synta Pharmaceuticals Corp. disclosed results Saturday from an interim analysis of the Phase IIb portion of its GALAXY (Ganetespib Assessment in Lung cAncer with docetaXel) trial of ganetespib, the company's lead heat-shock protein 90 (Hsp90) inhibitor, as second-line treatment in advanced non-small-cell lung cancer (NSCLC) at the European Society for Medical Oncology (ESMO) 2012 Congress in Vienna, Austria.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.